Regeneron Pharmaceuticals Finance Lease Liabilities (Total) remained flat by 0.0% to $720.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $720.00M to $720.00M. Over 5 years (FY 2020 to FY 2025), Finance Lease Liabilities (Total) shows relatively stable performance with a 0.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates higher reliance on lease-based financing for long-term assets, which increases fixed financial obligations and leverage ratios.
This represents the present value of future lease payments for assets where the lease term covers a major part of the as...
Comparable to debt obligations, this metric is analyzed alongside long-term borrowings to assess the total capital structure and financial risk profile of peer energy companies.
finance_lease_liabilities_total| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $719.70M | $720.00M | $720.00M | $720.00M | $720.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | +0.0% | +0.0% | +0.0% | +0.0% |